Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prospective, Multicenter, Open-label Study Evaluating the Effects of First-line Oral Combination Therapy of Macitentan and Tadalafil in Patients With Newly Diagnosed Pulmonary Arterial Hypertension (OPTIMA).

NCT02968901 is registered in ClinicalTrials.gov with Actelion as lead sponsor.

NCT NCT02968901
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02968901 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prospective, Multicenter, Open-label Study Evaluating the Effects of First-line Oral Combination Therapy of Macitentan and Tadalafil in Patients With Newly Diagnosed Pulmonary Arterial Hypertension (OPTIMA).
Lead sponsor
Actelion
Phase
Phase 4
Overall status
Terminated
Start date
September 1, 2015
Completion date
September 10, 2018
Enrollment
46 (actual)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

pulmonary arterial hypertension